Skip to content

EFFECT OF DAFLON (DIOSMIN AND HESPERIDIN) ON POST-OPERATIVE SEROMA FORMATION IN BREAST CANCER SURGERY''

EFFECT OF DAFLON (DIOSMIN AND HESPERIDIN) ON POST-OPERATIVE SEROMA FORMATION IN BREAST CANCER SURGERY

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07588828
Acronym
seroma
Enrollment
190
Registered
2026-05-15
Start date
2024-10-01
Completion date
2026-04-15
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Surgery, Post-operative Seroma Formation

Brief summary

Post-operative seroma formation remains one of the most common complications following breast cancer surgery. This prospective randomized controlled trial was conducted to evaluate the efficacy of Micronized Purified Flavonoid Fraction (Daflon) in reducing post-operative seroma formation in patients undergoing breast cancer surgery with sentinel lymph node biopsy or axillary lymph node dissection.

Detailed description

This single-center prospective randomized controlled study was conducted at the Breast Surgery Unit, Ittefaq Hospital Trust, Lahore. Female patients undergoing breast-conserving surgery or mastectomy with sentinel lymph node biopsy or axillary lymph node dissection for breast cancer were included. Participants were randomized into intervention and control groups according to surgical procedure strata. The intervention arm received Daflon 500 mg twice daily for four weeks post-operatively. Outcomes included seroma formation, drain output, and drain removal duration.

Interventions

DRUGDaflon (Diosmin and Hesperidin)

Patients received Daflon 500 mg orally twice daily for four weeks after breast cancer surgery.

Sponsors

Ittefaq Hospital trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients undergoing breast cancer surgery, including either breast-conserving surgery or mastectomy with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND), during the study period were included

Exclusion criteria

* Patients were excluded if they had pre-existing disease-related upper limb lymphedema, had undergone extensive oncoplastic procedures such as latissimus dorsi myocutaneaous flap (LDMF) or deep inferior epigastric perforator (DIEP) flap reconstruction, had a previously irradiated breast, or underwent only wide local excision under local anaesthesia in the setting of American Society of Anaesthesiologists (ASA) class IV or higher.

Design outcomes

Primary

MeasureTime frameDescription
post-operative seroma formation8 weeksreduction of post-operative seroma formation

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026